Treating obesity: Is it all in the gut?

Drug Discovery Today

Volumn 19, Issue 7, 2014, Pages 845-858

  Davenport, Richard J ^a   Wright, Susanne ^a  

^a Takeda Cambridge   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; AMYLIN; ANTIOBESITY AGENT; CHOLECYSTOKININ; CHOLECYSTOKININ A RECEPTOR; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HORMONE RECEPTOR; LORCASERIN; OXYNTOMODULIN; PHENTERMINE PLUS TOPIRAMATE; POLYPEPTIDE; TYROSINE; GASTROINTESTINAL HORMONE;

BARIATRIC SURGERY; BILIOPANCREATIC BYPASS; BINDING AFFINITY; BODY MASS; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DRUG TOLERABILITY; GASTRIC BAND; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RELEASE; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROCEDURES; REVIEW; SLEEVE GASTRECTOMY; STOMACH BYPASS; WEIGHT REDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GASTROINTESTINAL TRACT; METABOLISM; RISK FACTOR;

ANIMALS; ANTI-OBESITY AGENTS; BARIATRIC SURGERY; GASTROINTESTINAL HORMONES; GASTROINTESTINAL TRACT; HUMANS; OBESITY; RISK FACTORS;

EID: 84903787238     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.10.025     Document Type: Review

References (116)

1. Available at: http://www.who.int/mediacentre/factsheets/fs311/en
2. M. Aresu et al. Health Survey for England 2010 The NHS Centre for Health and Social Care
3. C.D. Byrne, and S. Wilde Review: orlistat and sibutramine are modestly effective for weight loss at 1 year ACP J. Club 142 2005 19
4. A.G. Powell et al. New drug targets for the treatment of obesity Clin. Pharmacol. Ther. 293 2011 43 53
5. Available at: http://ir.vivus.com/releasedetail.cfm?ReleaseID=631582
6. A.K. McGavigan, and K.G. Murphy Gut hormones: the future of obesity treatment? Br. J. Clin. Pharmacol. 74 2012 911 919
7. H.C. Diener et al. Topiramate in migraine prophylaxis - results from the placebo-controlled trial with propranol as an active control J. Neurol. 251 2004 943 950
8. Available at: http://ir.vivus.com/releasedetail.cfm?ReleaseID=650759
9. M.J. Menaster Weight gain, sexual dysfunction, and bupropion J. Clin. Psychiatry 66 2005 1335 1336
10. N.C. Latt et al. Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting Med. J. Aust. 176 2002 530 534 (Pubitemid 34649401)
11. Available at: http://ir.orexigen.com/phoenix.zhtml?c=207034&p=irol- newsArticle&ID=1432740&highlight
12. Available at: http://ir.orexigen.com/phoenix.zhtml?c=207034&p=irol- newsArticle&ID=1771665&highlight
13. Available at: http://invest.arenapharm.com/releasedetail.cfm?releaseid= 521977
14. Available at: http://invest.arenapharm.com/releasedetail.cfm?releaseid= 597830
15. Available at: http://invest.arenapharm.com/releasedetail.cfm?ReleaseID= 687182
16. Available at: http://invest.arenapharm.com/releasedetail.cfm?releaseid= 645020
17. D.R. Cottam et al. A case-controlled matched-pair cohort study of laparoscopic Roux-en-Y gastric bypass and Lap-Band patients in a single US centre with three year follow-up Obes. Surg. 16 2006 534 540 (Pubitemid 43781035)
18. L. Sjostrom et al. Obese Subjects Study Scientific Group. Lifestyle, diabetes and cardiovascular risk factors 10 years after bariatric surgery N. Engl. J. Med. 351 2004 2683 2693 (Pubitemid 39665322)
19. W.B. Browne et al. Laparoscopic gastric bypass is superior to adjustable gastric band in super morbidly obese patients: a prospective, comparable analysis Obes. Surg. 141 2006 683 689
20. P.R. Schauer et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes N. Engl. J. Med. 366 2012 1567 1576
21. G. Mingrone et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes N. Engl. J. Med. 366 2012 1577 1585
22. J.M. Kellum et al. Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty Ann. Surg. 211 1990 763 770
23. C.W. Le Roux et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters Ann. Surg. 243 2006 108 114 (Pubitemid 43054062)
24. R. Morinigo et al. GLP-1 PYY, hunger and satiety after gastric bypass surgery in morbidly obese subjects J. Clin. Endocrinol. Metab. 91 2006 1735 1740
25. H. Pajoughesh, and G.R. Lenz Medicinal chemical properties of successful central nervous system drugs NeuroTherpeutics 2 2005 541 553 (Pubitemid 41393264)
26. M.S. Alavijeh et al. Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery NeuroTherpeutics 2 2005 554 571 (Pubitemid 41393265)
27. K.G. Murphy, and S.R. Bloom Gut hormones and the regulation of energy homeostasis Nature 444 2006 854 859 (Pubitemid 46024992)
28. R.L. Batterham, and M.T. Neary Gut hormones: implications for the treatment of obesity Br. J. Clin. Pharmacol. 124 2009 44 56
29. C.X. Moore, and G.J. Cooper Co-secretion of amylin and insulin from cultured islet beta cells: modulation by nutrient secretagogues, islet hormones and hypoglycemic agents Biochem. Biophys. Res. Commun. 179 1991 1 9
30. P.C. Butler et al. Effects of meal ingestion on plasma amylin concentrations in NIDDM and nondiabetic humans Diabetes 39 1990 752 756 (Pubitemid 20218978)
31. A.A. Young et al. Dose responses for the slowing of gastric emptying in a rodent model by glucagonlike peptite (7-36) NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake Metabolism 45 1996 1 3 (Pubitemid 26104260)
32. S.R. Smith et al. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity Diabetes Care 31 2008 1816 1823
33. S.R. Smith et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy Obesity 17 2009 1736 1743
34. M. Kojima et al. Ghrelin is a growth hormone releasing acylated peptide from the stomach Nature 402 1999 656 660 (Pubitemid 129516334)
35. J. Yang et al. Identification of the acyltransferase that octanoylates ghrelin, an appetite stimulating peptide hormone Cell 132 2008 387 396 (Pubitemid 351192001)
36. C. De Vriese et al. Ghrelin degradation by serum and tissue homogenates: identification of the cleave sites Endocrinology 145 2004 4997 5005 (Pubitemid 39551118)
37. D.E. Cummings et al. A preprandial rise in plasma ghrelin levels suggest a role in meal initiation in humans Diabetes 50 2001 1714 1719 (Pubitemid 33641587)
38. H.S. Callahan et al. Postprandial suppression of plasma ghrelin levels is proportional to ingested calorific load but does not predict intermeal interval in humans J. Clin. Endocrinol. Metab. 89 2004 1319 1324 (Pubitemid 38368431)
39. D.L. Drazen et al. Effects of a fixed meal pattern on ghrelin secretion: evidence for a learned response independent of nutrient status Endocrinology 147 2006 23 30 (Pubitemid 43004258)
40. P. Kobelt et al. Anti-ghrelin Speigelmer NOX-B11 inhibits neurostimulatory and orexigenic effects of peripheral ghrelin in rats Gut 55 2006 788 792 (Pubitemid 43764547)
41. R.L. Batterham et al. Critical role for the peptide YY in protein-mediated satiation and body-weight regulation Cell Metab. 4 2006 223 233 (Pubitemid 44307976)
42. J. Korner et al. Differential effects of gastric bypass and banding on circulating gut hormone and leptin level Obesity 14 2006 1553 1561 (Pubitemid 46214822)
43. T.E. Adrian et al. Human distribution and release of a putative gut hormone, peptide YY Gastroenterology 89 1985 1070 1077 (Pubitemid 16231572)
44. D.R. Broom et al. The influence of the resistance and aerobic exercise on hunger, circulating levels of acylated ghrelin and peptide YY in healthy males Am. J. Physiol. Regul. Integr. Comp. Physiol. 296 2008 29 35
45. K. Chandarana et al. Subject standardization, acclimatization and sample processing affect gut hormone levels and appetite in humans Gastroenterology 136 2009 2115 2126
46. K. Beckh et al. Low hepatic clearance of peptide YY in the perfused rat liver Regul. Pept. 76 1992 473 478
47. Available at: http://www.7tm.com/News/News-Archive.aspx?M=News&PID= 45&NewsID=9
48. Available at: http://www.news-medical.net/news/20100918/Emispheree28099s- SNAC-drug-successful-in-reducing-food-intake3b-increasing-satiety.aspx
49. Available at: http://ir.emisphere.com/releasedetail.cfm?ReleaseID=508492
50. C. Orskov et al. Tissue and plasma concentrations of amidated and glycine rich glucagon-like peptide 1 in humans Diabetes 43 1994 535 539 (Pubitemid 24096293)
51. R. Mentlein et al. DPP-IV hydrolyses gastric inhibitory polypeptide, glucagon like peptide-1 (7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum Eur. J. Biochem. 214 1993 829 835 (Pubitemid 23188160)
52. C. Orskov et al. Secretion of the incretin hormones GLP-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day Scand. J. Gastroenterol. 31 1996 665 670 (Pubitemid 26290929)
53. C.R. Abbott et al. The inhibitory effect of peripheral administration of peptide YY and GLP-1 on food intake are attenuated by the ablation of the vaga-brainstem-hypothalmic pathway Brain Res. 1044 2005 127 131 (Pubitemid 40616060)
54. E. Naslund et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon and PYY release in humans Am. J. Physiol. 277 1999 910 916
55. F. Rodriquez de Fonseca Peripheral versus central effects of GLP-1 receptor agonists on satiety and body weight loss in Zucker obese rats Metabolism 79 2000 709 711
56. P.K. Chelikani et al. Intravenous infusion of GLP-1 potently inhibits food intake, sham feeding, and gastric emptying in rats Am. J. Physiol. Regul. Integr. Comp. Physiol. 288 2005 1695 1706
57. A. De Silva et al. The gut hormomes PKK (3-36) and GLP-1 (7-36 amide) reduce food intake and modulate brain activity in appetite centers in humans Cell Metab. 14 2011 709 717
58. P.J. Shiromani et al. Chapter 14 - Pharmacological treatment of obesity Sleep Loss and Obesity: Intersecting Epidemics 2012 Springer 203 225
59. T.E. Adrian et al. Distribution and release of pancreatic polypeptide Gut 17 1976 940 944
60. M.M. Berglund Recent developments in our understanding of the physiological role of PP-fold peptide receptor subtypes Exp. Biol. Med. 228 2012 217 244
61. F. Malaise-Lagae et al. Pancreatic polypeptide: a possible role in the regulation of food intake in the mouse Hypothesis Cell Mol. Life Sci. 33 1977 915 917
62. R.L. Batterham et al. Pancreatic polypeptide reduces appetite and food intake in humans J. Clin. Endocrinol. Metab. 88 2003 2989 3992
63. D.R. Jesudason et al. Low dose pancreatic polypeptide inhibits food intake in man Br. J. Nutr. 97 2007 426 429 (Pubitemid 46662029)
64. Available at: http://www.7tm.com/R-D.aspx
65. D. Bataille et al. Bioactivation enteroglucagon (oxyntomodulin): present knowledge on its chemical structure and its biological activities Peptides 2 1981 41 44 (Pubitemid 12118280)
66. L. Zhu et al. The role of DPPIV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide J. Biol. Chem. 278 2003 22418 22423 (Pubitemid 36830293)
67. M.A. Gatei et al. Molecular forms for human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper GI tract J. Clin. Endocrinol. Metab. 57 1983 488 495
68. A. Le Quellec et al. Oxyntomodulin like immunoreactivity: diurnal profile of a new potential enterogastrone J. Clin. Endocrinol. Metab. 74 1992 1405 1409
69. K. Wynne et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double blind randomized controlled trial Diabetes 54 2005 2390 2395 (Pubitemid 41134267)
70. M.A. Cohen et al. Oxyntomodulin suppresses appetite and reduces food intake in humans J. Clin. Endocrinol. Metab. 88 2003 4696 4701 (Pubitemid 37357514)
71. Available at: http://www.thepharmaletter.com/file/85453/thiakis-obesity- drug-enters-first-clinical-trial.html
72. Available at: http://www.pfizer.com/research/product-pipeline/product- pipeline
73. J.F. Rehfeld et al. The predominant cholecystokinin in human plasma and intestine is cholecystokinin-33 J. Clin. Endocrinol. Metab. 86 2001 251 258 (Pubitemid 32109804)
74. C. Rose et al. Characterization and inhibition of the cholecystokinin-inactivating serine peptidase Nature 380 1996 403 409 (Pubitemid 26102716)
75. J.M. Polak et al. Identification of cholecystokinin-secreting cells Lancet 2 1975 1016 1018
76. M. Dufrense et al. Cholecystokinin and gastrin receptors Physiol. Rev. 86 2006 508 847
77. J. Gibbs et al. Cholecystokinin decreases food intake in rats J. Comp. Physiol. Psychol. 84 1973 488 495
78. D.B. West et al. Cholecystokinin persistently suppresses meal size but not food intake in free feeding rats Am. J. Physiol. 246 1984 776 787
79. J. Jordan et al. Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients Clin. Pharmacol. Ther. 83 2008 281 287
80. P.H. Lee et al. Acute pancreatitis associated with Liraglutide Ann. Pharmacother. 44 2011 22
81. S.L. Anderson et al. Association of pancreatitis with GLP-1 agonist use Ann. Pharmacother. 44 2010 904 909
82. M. Elashoff et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies Gastroenterology 141 2011 150 156
83. Available at: http://pdf.reuters.com/htmlnews/8knews.asp?i= 43059c3bf0e37541&u=urn:newsml:reuters.com:20130226:nBw 266992a
84. Perrissoud, D. et al. (2006) Novel triazole derivatives as Ghrelin analogue ligands of growth hormone secretagogue receptors, Zentaris GMBH. Patent WO2007020013
85. Aicher, B. et al. (2011) Novel triazole derivatives with improved receptor activity and bioavailability properties as Ghrelin antagonists of growth hormone secretagogue receptors, Aeterna Zentaris GMBH. Patent WO2012035124
86. Available at: http://www.aezsinc.com/en/page.php?p=60&q=323
87. loxham, J. et al. (2011) Piperidine amides as modulators of the Ghrelin receptor, Prosidion, Patent WO2011117254
88. Garcia, R.S. et al. (2012) Asymmetric ureas and medical uses thereof, Helsinn Healthcare, Patent WO2012113103
89. Available at: http://www.bloomberg.com/apps/news?pid=newsarchive&sid= aYbX4h8ZElu0
90. Bhattacharya, S.A. et al. (2011) 2,3Dihydro-1H-inden-1-yl-2,7-diazaspiro [3.6] nonane derivatives and their use as antagonists or inverse agonists of the Ghrelin receptor, Pfizer. Patent WO2011114271
91. Baroni, M. et al. (2010) 3-Benzofuranyl-indol-2-one derivatives substituted at the 3 position, preparation thereof, and therapeutic uses thereof, Sanofi Aventis. Patent WO2010092289
92. Lange, B.H. et al. (2004) Ghrelin receptor inverse agonist for regulation of feeding behaviours, 7TM Pharma. Patent WO2004056869
93. 7TM Pharma A/S (2010) 7TM Pharma company website and pipeline. Available at: info@7tm.com
94. P.A. Carpino, and G. Ho Modulators of the Ghrelin system as potential treatments for obesity and diabetes Expert Opin. Ther. Pat. 18 2008 1253 1263
95. X. Zhu et al. GPR119 agonists: a novel strategy for type 2 diabetes treatment Diabetes Mellitus - Insights and Perspective 2013 59 82
96. A.A. Van Vliet et al. The novel GPR119-receptor agonist PSN821 shows glucose lowering and decreased energy intake in patients with T2DM after 14 days treatment 71st Annual Meeting and Scientific Sessions of the American Diabetes Association 2011
97. A. Joharapurkar et al. ZYOG1, a novel orally efficacious peptidomimetic GLP-1 receptor agonist 72nd Annual Meeting and Scientific Sessions of the American Diabetes Association 2012
98. A Single-Blinded, Randomized, Placebo-Controlled, Staggered-Parallel, Escalating-Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK-2374697 in Healthy Volunteers (2011) NCT01545570
99. Available at: http://www.ttpharma.com/PressReleases/2012/ 20121101TransTechPharmaPressRelease/tabid/248/Default.aspx
100. Beijing Hanmi Pharmaceutical: ChinaBio Partnering Forum 2013, May 29. http://www.ebdgroup.com/cbpf/participants/index.php
101. D. Chen et al. A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice Proc. Natl. Acad. Sci. U. S. A. 104 2007 943 948 (Pubitemid 46154716)
102. L.B. Knudsen et al. Small molecule agonists for the glucagon-like peptide-1 receptor Proc. Natl. Acad. Sci. U. S. A. 104 2006 937 942
103. M. Teng et al. Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor Bioorg. Med. Chem. Lett. 17 2007 5472 5478 (Pubitemid 47391264)
104. K.W. Sloop et al. Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets Diabetes 59 2010 3099 3107
105. N. Bernad et al. The design and synthesis of the high efficacy, non-peptide CCK1 receptor agonist PD-170292 Bioorg. Med. Chem. Lett. 10 2000 1245 1248 (Pubitemid 30345101)
106. J.E. Chin et al. Discovery of triazolobenzodiazepinone derivatives as orally active, gut-selective CCK1 receptor agonists for the potential treatment of obesity 239th American Chemical Society National Meeting and Exposition 2010
107. Cameron, K.O'K. et al. (2010) 1,2,4 Triazolo [4,3-A] [1,5] benzodiazapin-5 (6H)-ones as agonists of the cholecystokinin-1 receptor (CCK-IR), Pfizer. Patent WO2010067233
108. Available at: http://www.evaluategroup.com/Universal/View.aspx?type= Story&id=63064
109. J. Xu Metabolic Diseases Drug Discovery World Summit - SRI Conference (Part II), San Diego, CA. IDdb Meeting Report 2003
110. Bignon, E. et al. (2002) Triazole derivatives and pharmaceutical compositions comprising them, Sanofi Synthelabo. Patent WO2002034743
111. Sanofi Synthelabo (2004) Information meeting: February 2004. http://business.highbeam.com/436989/article-1G1-113441013/sr-146131- sanofisynthelabo-discontinued-europe
112. T.G. Holt et al. Pyrimidine carboxamides as potent and selective CCK1R agonists 240th American Chemical Society National Meeting and Exposition 2010
113. Berger, R. et al. (2007) Substituted imidazole-4-carboxamides as cholecystokinin-1 receptor modulators, Merck & Co. Patent WO2007120688
114. R. Berger et al. 2-Substituted piperazine-derived imidazole carboxamides as potent and selective CCK1R agonists for the treatment of obesity Bioorg. Med. Chem. Lett. 18 2008 4833 4837
115. L. Wang et al. Discovery of pyrimidine carboxamides as potent and selective CCK1 receptor agonists Bioorg. Med. Chem. Lett. 21 2011 2911 2915
116. C.A. Lipinski et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 23 1997 3 25 (Pubitemid 27046991)